Dirk De Herdt
Dirk has over 25 years' experience in the global life sciences industry, with a proven track-record in corporate strategy, product development and financing activities. Prior to founding LFSCNC, he worked as an independent consultant advising several pharma and biotech clients. He previously worked at Oxurion where he served as Head of Program Management, successfully advancing the company’s portfolio of projects into the next development stages. As part of the company's Management Team, he was also instrumental in supporting financing rounds and other business development activities. Prior to Oxurion, he served in various senior-level development roles at TiGenix and Johnson & Johnson. Dirk holds a PharmD degree from the University of Antwerp and completed an executive management programme at the Vlerick Business School. Dirk is also a certified Qualified Person.
Koen is an executive with over 20 years of experience in executive management of pharmaceutical development, early clinical stage to commercial manufacturing and supply chain operations and technology transfer of biopharmaceutical and Advanced Therapy Medicinal Products (ATMPs). Before founding LFSCNC, he has supported various cell- and gene therapy clients in Europe, USA and Asia in a consulting role. Prior to setting up his consulting firm, Koen established the manufacturing and quality assurance units at TiGenix and was instrumental the development and EU approval of ChondroCelect and successful IPO of TiGenix. Koen holds a PharmD and Industrial Pharmacist degree from the Universities of Leuven and Antwerp, and is a Postgraduate in Business Management from the University of Leuven. Koen is a Certified EU Qualified Person.
Peter has over 25 years of corporate, R&D, business and executive management experience in the life sciences industry. Before joining LFSCNC, he worked as an independent consultant providing strategic advice to pharma and biotech clients. He previously served as R&D Director at TiGenix where he was responsible for pipeline portfolio development and was part of the team that successfully developed TiGenix' lead compound. Prior to TiGenix, Peter co-founded Galapagos and was named R&D Director where he established the technology platform in a large number of therapeutic areas. Peter also served on the Management Teams of both companies and was part of the teams that successfully concluded the IPO of Galapagos and TiGenix, respectively. Before joining Galapagos, he was a Director at Tibotec and part of the drug discovery team for HIV and HCV. Peter also co-founded CBD Technologies and was involved in the establishment of Arcarios, a young drug development company for bone and joint diseases. He earned his PhD in Biochemistry from the University Ghent, Belgium.